Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.00 USD
-0.14 (-2.72%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EDIT 5.00 -0.14(-2.72%)
Will EDIT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Other News for EDIT
Commit To Buy Editas Medicine At $2.50, Earn 14% Using Options
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
Earnings week ahead: MSFT, AMZN, AAPL, META, PFE, MCD, SBUX, XOM, CVX and more
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition